Tirofiban

Nexus Pharmaceuticals Inc. Receives FDA Approval for Tirofiban Hydrochloride Injection

Retrieved on: 
Thursday, February 9, 2023
FDA, Health, General Health, Pharmaceutical, Cardiology, Biotechnology, Nexus, Food, AP, Food and Drug Administration, Merrell Dow Pharmaceuticals Inc. v. Thompson, US Foods, IV, Patient, Tirofiban, Injection, Pharmaceutical industry

Nexus Pharmaceuticals Inc. announced that it has received US Food and Drug Administration (FDA) approval for Tirofiban Hydrochloride Injection in 5mg/100mL single-dose IV-bags.

Key Points: 
  • Nexus Pharmaceuticals Inc. announced that it has received US Food and Drug Administration (FDA) approval for Tirofiban Hydrochloride Injection in 5mg/100mL single-dose IV-bags.
  • Tentative approval has been granted for concentrations of 12.5mg/250mL single-dose IV-bags.
  • “Being granted this approval is a milestone for us, but also for patients who want more transparency in the healthcare they receive.
  • We eagerly anticipate bringing it to market in the coming months.”
    Nexus Pharmaceuticals’ Tirofiban Hydrochloride for Injection will be available in cartons of sole single-dose IV bags.

Cipher Pharmaceuticals Reports Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 11, 2022
Telephone, Psoriasis, Degenerative disease, TSX, Adjustment, Plasma protein binding, Marketing, Sun, EBITDA, CDN, Food, SEDAR, Industry, Management, American, Partnership, Tax, Safety, Eflornithine, Privacy, Webcast, Rheumatoid arthritis, Regulation of tobacco by the U.S. Food and Drug Administration, Intellectual property, Interim, Substance-related disorder, Growth, Hospital, Compliance, European, Income, Moberg, COVID-19, Acquisition, IFRS, Coronavirus, Tirofiban, Goal, Mission statement, Onychomycosis, FDA, Hope, Conversation, Company, Depreciation, Risk, Financial statement, Insurance, CPH, III, Adoption, Weapon, Cryptocurrency, Pharmaceutical industry, Fossil fuel, Online gambling, Mobile phone, Bookkeeping, MISSISSAUGA, Isotretinoin, IQVIA, Isotretinoin

(All figures are in U.S. dollars)

Key Points: 
  • (All figures are in U.S. dollars)
    Strong balance sheet with $24.2 million in cash at June 30, 2022
    MISSISSAUGA, ON, Aug. 11, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three and six month periods endedJune 30, 2022.
  • Craig Mull, Interim CEO commented,"We are pleased to report that Cipher delivered another strong quarter, generating positive net income and cash from operating activities.
  • Cipher will hold a conference call onAugust 12, 2022, at8:30 a.m. (ET)to discuss its financial results and other corporate developments.
  • Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products.

Cipher Pharmaceuticals Reports Strong First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 12, 2022
CPH, Telephone, Company, Eflornithine, Conversation, Mission statement, EBITDA, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Depreciation, Webcast, Sun Pharma, Moberg, Goal, Insurance, SEDAR, Tax, Coronavirus, Risk, March 31, Privacy, COVID-19, Marketing, Adjustment, TSX, Tirofiban, FDA, Hope, Industry, Sun, Substance-related disorder, Partnership, Intellectual property, Compliance, Hospital, Management, Financial statement, Onychomycosis, IFRS, Adoption, Acquisition, Growth, Interim, Degenerative disease, Weapon, Online gambling, Pharmaceutical industry, Fine chemical, Renewable energy, Mobile phone, Bookkeeping, Isotretinoin, MISSISSAUGA, IQVIA, Isotretinoin

Our strong results have been driven by our reduced cost structure in addition to improved distribution and supply agreements."

Key Points: 
  • Our strong results have been driven by our reduced cost structure in addition to improved distribution and supply agreements."
  • During the first quarter, Cipher announced an extension of the distribution and supply agreement with Sun Pharmaceutical Industries ("Sun Pharma") through December 31, 2026.
  • This extension will provide Cipher with an additional four years of visibility into stable revenue and cashflow on the isotretinoin portfolio.
  • Cipher will hold a conference call onMay 13, 2022, at8:30 a.m. (ET)to discuss its financial results and other corporate developments.

Medicure Announces Early Completion of Enrollment for iSPASM, a Phase 1/2a Exploratory Clinical Trial of AGGRASTAT® (tirofiban hydrochloride) Injection vs. Placebo for Induced Suppression of Platelets Activity in Aneurysmal Subarachnoid Hemorrhage Manage

Retrieved on: 
Wednesday, January 27, 2021
Glycoprotein IIb/IIIa inhibitors, Piperidines, Chemical compounds, Sulfonamides, Tirofiban, Organic compounds, Peptides, Bivalirudin

Dr. Hasan expects to release top-line data and present the results at an upcoming conference with a manuscript to follow.

Key Points: 
  • Dr. Hasan expects to release top-line data and present the results at an upcoming conference with a manuscript to follow.
  • Results from this study pave the way for a Phase 2 trial which will be focused on efficacy.
  • We are very grateful for the sponsorship and partnership with Medicure for making this trial happen to benefit our patients."
  • As of this time, neither AGGRASTATnor any of the GP IIb/IIIa inhibitors are indicated for the use in stroke patients.

Medicure Announces Settlement of Patent Infringement Action

Retrieved on: 
Wednesday, November 18, 2020
Intellectual property law, Monopoly, Patent, Tirofiban, Generic drug, United States patent law

WINNIPEG, MB, Nov. 18, 2020 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today announces that its subsidiary, Medicure International Inc., has settled its ongoing patent infringement action against Nexus Pharmaceuticals, Inc. ("Nexus") in the U.S. District Court for the Northern District of Illinois, which alleged infringement of Medicure's U.S. Patent No.6,770,660 ("the '660 patent").

Key Points: 
  • WINNIPEG, MB, Nov. 18, 2020 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today announces that its subsidiary, Medicure International Inc., has settled its ongoing patent infringement action against Nexus Pharmaceuticals, Inc. ("Nexus") in the U.S. District Court for the Northern District of Illinois, which alleged infringement of Medicure's U.S. Patent No.6,770,660 ("the '660 patent").
  • As part of the settlement, Nexus has acknowledged that the '660 patent is valid, enforceable and infringed.
  • The Company had filed the patent infringement action against Nexus alleging infringement of the '660 patent.
  • The patent infringement action was in response to Nexus' filing of an abbreviated new drug application (ANDA) seeking approval from the U.S. Food and Drug Administration ("FDA") to market a generic version of AGGRASTAT (tirofiban hydrochloride) injection before the expiration of the '660 patent.

Medicure Announces AGGRASTAT® Shows Promise in Treating Thrombotic Complications Due to COVID-19 in Early Clinical Reports

Retrieved on: 
Monday, August 24, 2020
Health, Articles, Clinical research, Drug discovery, Pharmaceutical industry, Piperidines, Sulfonamides, Tirofiban, Clinical trial, Coronavirus disease, Thrombosis

WINNIPEG, MB, Aug. 24, 2020 /PRNewswire/ -Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, is reporting that early investigator sponsored clinical reports evaluating the efficacy of AGGRASTAT(tirofiban hydrochloride) show promise for preventing and treating thrombotic complications due to COVID-19.

Key Points: 
  • WINNIPEG, MB, Aug. 24, 2020 /PRNewswire/ -Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, is reporting that early investigator sponsored clinical reports evaluating the efficacy of AGGRASTAT(tirofiban hydrochloride) show promise for preventing and treating thrombotic complications due to COVID-19.
  • Seven other small clinical reports have recently been published exploring the clinical efficacy of AGGRASTATin patients with COVID-19.
  • Medicure is evaluating sponsorship of further US-based randomized clinical studies to rapidly assess the efficacy and safety of using AGGRASTATfor preventing thrombotic complications due to COVID-19.
  • "We believe there is reason to sponsor this type of clinical research due to the emerging understanding of the role of thrombosis in the pathophysiology of COVID-19."

Medicure Announces Positive Results for AGGRASTAT® in the FABOLUS-FASTER Trial and Publication in the Journal - Circulation

Retrieved on: 
Monday, June 29, 2020
Chemical compounds, Organic compounds, GpIIb/IIIa inhibitors, Psychology, Piperidines, Cangrelor, Nucleotides, Organochlorides, Thioethers, Tirofiban, Inferiority complex

The results from the FABOLUS-FASTER trial showed cangrelor did not reach non-inferiority with tirofiban; in fact, tirofiban achieved superior IPA over cangrelor at 30 minutes (95.0%9.0% vs 34.1%22.5%; P

Key Points: 
  • The results from the FABOLUS-FASTER trial showed cangrelor did not reach non-inferiority with tirofiban; in fact, tirofiban achieved superior IPA over cangrelor at 30 minutes (95.0%9.0% vs 34.1%22.5%; P
  • Complete results from this study were published on June 27, 2020 in Circulation, a peer-reviewed journal of the American Heart Association.
  • As of this time, neither AGGRASTATnor any of the GP IIb/IIIa inhibitors are indicated for the use in STEMI patients.
  • Cangrelor, Tirofiban and Chewed or Standard Prasugrel Regimens in Patients with ST-Segment Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial.Circulation.

Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT® will be Presented at the PCR e-Course, Late Breaking Trial Sessions, June 27, 2020

Retrieved on: 
Monday, June 15, 2020
Chemistry, Physical sciences, Natural sciences, Laboratory techniques, Molecular biology, Biotechnology, Hoffmann-La Roche, Cangrelor, Polymerase chain reaction, Tirofiban

Dr. Valgimigli's presentation will take place during a late-breaking trial session at the PCR e-Course 2020, on Saturday, June 27at 9:00 am CET / 3:00 am EDT.

Key Points: 
  • Dr. Valgimigli's presentation will take place during a late-breaking trial session at the PCR e-Course 2020, on Saturday, June 27at 9:00 am CET / 3:00 am EDT.
  • FABOLUS-FASTER is a randomized, open-label, multi-center trial comparing AGGRASTAT to cangrelor in patients with ST-elevation myocardial infarction referred for PCI*.
  • To register and participate in the PCR e-Course, click here: https://www.pcronline.com/Courses/PCR-e-Course
    The content will remain available on replay during and after the e-Course.
  • Complete results from this study have been accepted for publication in Circulation, a peer-reviewed journal of the American Heart Association.

Correvio Partners with Hong Kong Teson Pharma Limited for the Commercialization of Aggrastat® in China

Retrieved on: 
Tuesday, March 10, 2020
Piperidines, Sulfonamides, Tirofiban, Pharma

VANCOUVER and HONG KONG, March 10, 2020 /PRNewswire/ -Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, and Hong Kong Teson Pharma Limited (Teson), a privately-held pharmaceutical company, today announced that Correvio International Srl, a wholly owned subsidiary of Correvio, and Teson have entered into an exclusive agreement for the commercialization of Aggrastat (tirofiban hydrochloride).

Key Points: 
  • VANCOUVER and HONG KONG, March 10, 2020 /PRNewswire/ -Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, and Hong Kong Teson Pharma Limited (Teson), a privately-held pharmaceutical company, today announced that Correvio International Srl, a wholly owned subsidiary of Correvio, and Teson have entered into an exclusive agreement for the commercialization of Aggrastat (tirofiban hydrochloride).
  • Under the terms of the agreement, Correvio will receive a one-time upfront payment of $3.0 million (USD) from Teson.
  • Hong Kong Teson Pharma Limited is a privately-held pharmaceutical company in Hong Kong, China, focusing on commercializing innovative and cutting-edge therapies and medications to address the unmet medical needs in the Asia Pacific region.
  • Correvio and the Correvio Logo are the proprietary trademarks of Correvio Pharma Corp.
    Aggrastat and Brinavess are trademarks owned by Correvio and its affiliates worldwide.

Medicure Announces the Completion of Shortened AGGRASTAT® Versus Integrilin® in Percutaneous Coronary Intervention (SAVI-PCI) Study

Retrieved on: 
Tuesday, December 17, 2019
GpIIb/IIIa inhibitors, Chemical compounds, Organic compounds, Piperidines, Sulfonamides, Tirofiban, Eptifibatide, Percutaneous coronary intervention, AGG, Cardiology, Glycoprotein IIb/IIIa inhibitors

WINNIPEG, Dec. 17, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the completion of the Shortened AGGRASTAT (tirofiban hydrochloride) injection versus Integrilin (eptifibatide) in Percutaneous Coronary Intervention (SAVI-PCI) Clinical Trial.

Key Points: 
  • WINNIPEG, Dec. 17, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the completion of the Shortened AGGRASTAT (tirofiban hydrochloride) injection versus Integrilin (eptifibatide) in Percutaneous Coronary Intervention (SAVI-PCI) Clinical Trial.
  • Topline results of the SAVI-PCI trial will be communicated in a subsequent press release in Q1 of 2020.
  • The study reflects our investment in the Aggrastat brand, and our partnership with leading cardiologists across the United States, providing clinical data involving Aggrastat that reflects contemporary practice", said Albert Friesen, PhD, CEO of Medicure.
  • AGGRASTAT can cause serious bleeding.Most bleeding associated with AGGRASTAT occurs at the arterial access site for cardiac catheterization.